Bone Therapeutics will host the Annual General Meeting and Extraordinary General Meeting on June 8, 2022
The preliminary documents for the Annual and Extraordinary General Meeting have been made available on the company’s website
Notices of meetings, including the agenda and voting proposals, are published today in the
The preliminary documents and information relating to these meetings have been made available and can be consulted on the Bone Therapeutics website, Investors / General Meeting section, in accordance with the applicable legal and regulatory provisions.
It is also possible to receive the documents free of charge upon request by email to [email protected] or by telephone on +32 (0)493 09 73 66. The documents are also available at the Company’s registered office, Rue Granbonpré 11,
Bone Therapeutics’ core technology is based on its state-of-the-art allogeneic cell and gene therapy platform with differentiated mesenchymal stromal cells (MSCs) from bone marrow that can be stored at the point of use in the hospital. His The lead investigational drug, ALLOB, represents a proprietary and unique approach to bone regeneration that transforms undifferentiated stromal cells from healthy donors into bone-forming cells. These cells are produced through Bone Therapeutics’ scalable manufacturing process. Following the approval of the CTA by the regulatory authorities in
Bone Therapeutics cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by an extensive IP (Intellectual Property) portfolio spanning ten patent families as well as know-how. The Company is based in the Louvain-la-New
For more information, please contact:
Tel: +32 (0)493 09 73 66
For Belgian media and investor enquiries:
Tel: +32 (0)488 40 44 77
For French media and investor enquiries:
NewCap Investor Relations
Tel: +33 (0)1 44 71 94 94
Certain statements, beliefs and opinions contained in this press release are forward-looking and reflect the current expectations and projections of the Company or, if applicable, the directors of the Company regarding future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including but not limited to changes in demand, competition and technology, may cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Accordingly, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to the forward-looking statements contained in this press release. as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which such forward-looking statements are based. Neither the Company, nor its advisers or representatives, nor any of its subsidiaries or the officers or employees of such persons warrant that the assumptions underlying these forward-looking statements are free from error and accept no responsibility for the future accuracy of forward-looking statements. statements contained in this press release or the actual occurrence of anticipated developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.